Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-10 · accession 0000912282-25-001407 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | 2025-12-10 | QNCX | Thye Dirk | CEO, CMO, Dir | G - Gift | $0.00 | -739.9K | 255.0K | -74% | $0 | |
| I | 2025-12-12 | 2025-12-10 | QNCX | Thye Dirk | CEO, CMO, Dir | G - Gift | $0.00 | +739.9K | 739.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-12-10 | G | D | 739,885 | $0.00 | 255,000 | D Thye Trust | — | — | |
| 2 | Common | Common Shares | 2025-12-10 | G | A | 739,885 | $0.00 | 739,885 | I | — | — |